Selinexol Medication Guide, Dosage

Selinisol (Xpovio, Xpovio) is the world's first oral selective nuclear export protein (XPO1) inhibitor with a new mechanism. It is mainly used to treat adult patients with relapsed or refractory multiple myeloma who have previously received treatment and are refractory to at least one proteasome inhibitor, one immunomodulator, and one anti-CD38 monoclonal antibody. In addition, selinesol has also shown certain efficacy in the treatment of relapsed/span>refractory diffuse large B cell lymphoma.

While selinesol offers hope to many patients, it is not suitable for everyone. Pregnant and lactating women, children, and patients allergic to its ingredients should avoid using this medicine or use it with caution, and make choices under the guidance of a doctor.

Selinesol has a synergistic effect with chemotherapy drugs, proteasome inhibitors, immunomodulators and CD38 monoclonal antibodies. However, patients should pay close attention to possible drug interactions when using these drugs together and make adjustments according to their doctor's recommendations.

When used in combination with bortezomib and dexamethasone(SVd), take 100 mg orally once weekly on day 1 of the week. When used in combination with dexamethasone, take 80 orally on days 1 and 3 of each week. mg, until disease progression or unacceptable toxicity, 20 mgselinesol per dose orally on days 1 and 3 of each week in combination with dexamethasone. For routine adults with lymphoma, take 60 mg orally on days 1 and 3 of each week.

Patients should pay close attention to their physical condition while taking selinesol. If you find any serious side effects, you should seek medical advice immediately and seek professional advice. At the same time, regular inspection and monitoring are also essential to ensure the effectiveness and safety of the medicine.